Connect Biopharma Holdings (CNTB) Change in Acquisitions & Divestments (2024 - 2026)

Connect Biopharma Holdings (CNTB) has reported Change in Acquisitions & Divestments for 3 consecutive years, with $6.0 million the latest figure, recorded in Q1 2026.

• Quarterly Change in Acquisitions & Divestments rose 200.0% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $44.7 million (up 713.09% YoY) and the FY2025 annual result came in at $40.7 million, up 219.37% from the prior year.
• Change in Acquisitions & Divestments fell to $6.0 million in Q1 2026 per CNTB's latest filing, from $11.0 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for CNTB reached as high as $14.4 million in Q3 2025 and fell as low as $2.0 million in Q1 2025.
• A 3-year average of $8.5 million and a median of $9.2 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• The largest YoY upside for Change in Acquisitions & Divestments was 281.14% in 2025 against a maximum downside of 78.38% in 2025.
• Year by year, Change in Acquisitions & Divestments stood at $3.5 million in 2024, then soared by 214.29% to $11.0 million in 2025, then slumped by 45.45% to $6.0 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $6.0 million, $11.0 million, and $14.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.